4/2/2012 7:37:27 AM
A new once-daily AIDS drug from GlaxoSmithKline and its partner Shionogi proved just as good as Merck & Co's twice-daily rival Isentress in a late-stage clinical trial, boosting hopes for the product. Both GSK's new drug dolutegravir and Isentress are so-called integrase inhibitors, a novel class of drugs for fighting HIV/AIDS that block the virus causing the disease from entering cells. Dolutegravir is important for GSK since it could help rejuvenate its HIV/AIDS business - an area of medicine it used to dominate but where it has fallen behind rivals in recent years.
comments powered by